Bonneville-Levard, Alice; Frappaz, Didier; Tredan, Olivier; Lavergne, Emilie; Corset, Veronique; Agrapart, Vincent; Chabaud, Sylvie; Pissaloux, Daniel; Wang, Qing; Attignon, Valery; Cartalat, Stephanie; Ducray, Francois; Thomas-Maisonneuve, Laure; Honnorat, Jerome; Meyronet, David; Taillandier, Luc; Blonski, Marie; Viari, Alain; Baudet, Christian; Sohier, Emilie; Lantuejoul, Sylvie; Paindavoine, Sandrine; Treilleux, Isabelle; Rodriguez, Christine; Perol, David; Blay, Jean-Yves published the artcile< Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial>, Reference of 112-63-0, the main research area is brain tumor mol profile personalized medicine; Decision-making; Molecular profiling; Precision medicine; Primary brain tumor; Targeted therapy.
Abstract: Immunohistochem. and recent mol. technologies progressively guided access to personalized anti-tumoral therapies. We explored the feasibility, efficacy, and the impact of mol. profiling in patients with advanced brain tumors. This multicentric prospective trial ProfiLER enrolled patients with primary brain tumors, who have been pre-treated with at least one line of anti-cancer treatment, and for whom mol. profiles had been achieved using next-generation sequencing and/or comparative genomic hybridization on fresh or archived samples from tumor, relapse, or biopsies. A mol. tumor board weekly analyzed results and proposed mol.-based recommended therapy (MBRT). From Feb. 2013 to Dec. 2015, we enrolled 141 patients with primary brain tumor and analyzed 105 patients for whom tumor genomic profiles had been achieved. Histol. mainly identified glioblastoma (N = 46, 44%), low-grade glioma (N = 26, 25%), high-grade glioma (N = 12, 11%), and atypical and anaplastic meningioma (N = 8, 8%). Forty-three (41%) patients presented at least one actionable mol. alteration. Out of 61 alterations identified, the most frequent alterations occurred in CDKN2A (N = 18), EGFR (N = 12), PDGFRa (N = 8), PTEN (N = 8), CDK4 (N = 7), KIT (N = 6), PIK3CA (N = 5), and MDM2 (N = 3). Sixteen (15%) patients could not be proposed for a MBRT due to early death (N = 5), lack of available clin. trials (N = 9), or inappropriate results (N = 2). Only six (6%) of the 27 (26%) patients for whom a MBRT had been proposed finally initiated MBRT (everolimus (N = 3), erlotinib (N = 1), ruxolitinib (N = 1), and sorafenib (N = 1)), but discontinued treatment for toxicity (N = 4) or clin. progression (N = 2). High-throughput sequencing in patients with brain tumors may be routinely performed, especially when macroscopic surgery samples are available; nevertheless delays should be reduced. Criteria for clin. trial enrollment should be reconsidered in patients with brain tumors, and a panel of genes specifically dedicated to neurol. tumors should be developed to help decision-making in clin. practice.
Medical Oncology (New York, NY, United States) published new progress about Antitumor agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Reference of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics